@RecursiveChris@mkoeris@Tesla 🎯 again I don’t love the tech/auto analogue BUT their respective “halo” or moonshot tech products showcasing the bleeding edge of innovation, often trickles down to, and benefits consumer accessible products…
We’re building an AIxBio company. The hard part is the biology. The operating model we are striving towards is new - it is what this Replit post describes - a small team running development, BD, legal, finance, and ops through agents instead of building a full headcount for each. https://t.co/FnQD2VwR1p
$600M up front + biobucks up to $15.B total. It’s 2026 and Big Pharma is handily beating China touring VCs to the punch and getting the drugs directly vs the dilutive, expensive and oft inefficient newco arbitrage models.
There is a solution for US to compete - and no Biosecure Act saber rattling isn’t it.
AI, Automation, bet on next gen founders, ween out journeymen execs with tired playbooks.